#1 Clinical Trials Search in Europe

Methylprednisolone Hemisuccinate

This article examines the use of Methylprednisolone Hemisuccinate in clinical trials for different medical conditions. Methylprednisolone Hemisuccinate is a corticosteroid medication with anti-inflammatory and immunosuppressive properties. Clinical trials are investigating its effectiveness in treating conditions such as multiple sclerosis, sudden hearing loss, and post-surgical inflammation. We’ll explore the potential benefits, dosing methods, and comparisons with other treatments being studied.

Table of Contents

What is Methylprednisolone Hemisuccinate?

Methylprednisolone hemisuccinate is a powerful anti-inflammatory medication that belongs to a class of drugs called corticosteroids. It is a synthetic version of hormones naturally produced by your adrenal glands. This medication is known by several names, including methylprednisolone, MP, Solu-Medrol, and Urbason[1]. Understanding these alternative names can help you recognize the medication if it’s prescribed under a different label.

Medical Uses

Methylprednisolone hemisuccinate is used to treat a variety of conditions characterized by inflammation or autoimmune responses. Some of the conditions it’s commonly used for include:

  • Multiple Sclerosis (MS): It’s used to manage acute exacerbations (flare-ups) of MS[2].
  • Idiopathic Sudden Sensorineural Hearing Loss (ISSHL): This is a type of sudden hearing loss, and methylprednisolone is considered a first-line treatment for this condition[3].
  • Membranous Nephropathy: This is a kidney disorder where methylprednisolone is used as part of the treatment regimen[1].
  • Acute Severe Asthma: The medication is used to manage severe asthma attacks[4].
  • Post-operative Inflammation: It’s used to control inflammation after various types of surgeries, including cataract surgery[5].

How is it Administered?

Methylprednisolone hemisuccinate can be administered in several ways, depending on the condition being treated:

  • Intravenous (IV) Infusion: For conditions like multiple sclerosis or severe asthma, it’s often given as an IV infusion. The dose and duration can vary. For example, in some MS studies, doses ranged from 150mg to 1000mg[2].
  • Oral Tablets: In some cases, it may be given as oral tablets, especially for longer-term treatment[1].
  • Intratympanic Injection: For sudden hearing loss, it may be injected directly into the middle ear. In one study, a concentration of 62.5 mg/ml was used[6].
  • Eye Drops: For post-operative inflammation in eye surgeries, it may be administered as eye drops[5].

Effectiveness

The effectiveness of methylprednisolone hemisuccinate varies depending on the condition being treated:

  • In multiple sclerosis, it has been shown to help manage acute exacerbations and potentially improve recovery[2].
  • For sudden hearing loss, it’s considered a first-line treatment, although more research is ongoing to fully understand its effectiveness[3].
  • In post-operative inflammation, especially after eye surgeries, it has been shown to be effective in controlling inflammation[5].

Potential Side Effects

While methylprednisolone hemisuccinate can be very effective, it can also cause side effects. Some potential side effects include:

  • Changes in blood glucose levels
  • Effects on the hypothalamic-pituitary-adrenal (HPA) axis, which controls hormone production
  • Changes in bone metabolism, potentially affecting osteocalcin concentrations
  • Effects on the immune system, potentially altering lymphocyte counts
  • Changes in complement factors, which are part of your immune system

It’s important to note that these side effects are being closely monitored in ongoing studies[2]. Always discuss potential side effects with your healthcare provider.

Ongoing Research

Several clinical trials are currently underway to further understand the effectiveness and optimal use of methylprednisolone hemisuccinate:

  • A study is comparing its effectiveness to hydrocortisone in treating acute severe asthma[4].
  • Another trial is investigating its use in combination with other medications for treating membranous nephropathy[1].
  • Research is also being conducted on its effectiveness when administered as intratympanic injections for Ménière’s disease, a disorder of the inner ear[6].

These ongoing studies aim to provide more information about the best ways to use methylprednisolone hemisuccinate and potentially expand its applications in treating various conditions.

Aspect Details
Conditions Studied Multiple Sclerosis, Sudden Hearing Loss with Obstructive Sleep Apnea, Post-surgical inflammation in eye surgeries
Administration Methods Intravenous infusions, Intratympanic injections
Comparison Treatments Placebo, Other prednisolone formulations
Primary Outcomes Measured Safety and tolerability, Pharmacokinetics, Hearing threshold recovery, Control of post-operative inflammation
Secondary Outcomes Changes in CNS functioning, Hormone levels, Blood glucose levels, Osteocalcin concentrations, Lymphocyte count
Study Designs Randomized, double-blind, placebo-controlled, crossover studies

FAQ

  • What is Methylprednisolone Hemisuccinate? Methylprednisolone Hemisuccinate is a corticosteroid medication with anti-inflammatory and immunosuppressive properties. It's being studied in clinical trials for various medical conditions.
  • What conditions are being studied with Methylprednisolone Hemisuccinate? Clinical trials are investigating its use in conditions such as multiple sclerosis, sudden hearing loss associated with obstructive sleep apnea, and post-surgical inflammation in eye surgeries.
  • How is Methylprednisolone Hemisuccinate administered in these trials? The medication is administered in different ways depending on the study, including intravenous infusions and intratympanic injections (injections into the middle ear).
  • Are there any side effects associated with Methylprednisolone Hemisuccinate? While specific side effects aren't mentioned in the trial summaries, corticosteroids can have side effects. The trials are monitoring for adverse events and comparing the safety profile to other treatments or placebo.
  • How does Methylprednisolone Hemisuccinate compare to other treatments in these trials? Some trials are comparing Methylprednisolone Hemisuccinate to placebo or other active treatments. For example, in eye surgery trials, it's being compared to other formulations of prednisolone to assess its effectiveness in controlling post-operative inflammation.

Ongoing Clinical Trials on Methylprednisolone Hemisuccinate

  • Study on Early Immunotherapy with Human Normal Immunoglobulin, Cyclophosphamide, and Methylprednisolone for Patients with Anti-Hu Paraneoplastic Sensory Neuropathy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Methylprednisolone and Methoxsalen for Treating Grade II Acute Graft-Versus-Host Disease in Adult Stem Cell Transplant Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Corticosteroids and Rituximab to Prevent Worsening of Ocular Myasthenia Gravis in Newly Diagnosed Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study on Pioglitazone for Improving Kidney Health in Patients with ANCA-Associated Vasculitis

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on the Effect of Methylprednisolone Injection for Reducing Swelling, Stiffness, and Pain After Lower Wisdom Tooth Surgery in Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

  • Study on High-Dose Methylprednisolone and Prednisolone for Children with Stroke Due to Focal Cerebral Arteriopathy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark France Germany Sweden

  • Study on the Effectiveness of Tocilizumab, Methylprednisolone, and Prednisone for Patients with Acute Anterior Ischemic Optic Neuropathy in Giant Cell Arteritis

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Safety and Tolerability Study of AB-1001 Brain Injection in Adults with Early Huntington’s Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Methylprednisolone and Sodium Chloride in Patients Undergoing Surgery for Digestive Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Methylprednisolone Hemisuccinate: A corticosteroid medication with anti-inflammatory and immunosuppressive properties, being studied in various clinical trials.
  • Clinical trial: A research study that tests how well new medical approaches work in people, often comparing a new treatment to a standard one, a placebo, or no treatment.
  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerves.
  • Idiopathic Sudden Sensorineural Hearing Loss (ISSHL): Unexplained rapid loss of hearing, often affecting only one ear, which occurs over a period of less than 72 hours.
  • Obstructive Sleep Apnea (OSA): A sleep disorder characterized by repeated episodes of complete or partial obstruction of the upper airway during sleep.
  • Intratympanic injection: A medical procedure where medication is injected directly into the middle ear space.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of their action.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the drug being tested.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT01955187
  2. https://clinicaltrials.gov/study/NCT02048358
  3. https://clinicaltrials.gov/study/NCT04192656
  4. https://clinicaltrials.gov/study/NCT06171932
  5. https://clinicaltrials.gov/study/NCT01227876
  6. https://clinicaltrials.eu/trial/study-on-menieres-disease-comparing-methylprednisolone-and-placebo-for-patients-with-unilateral-menieres-disease/